Adjuvant endocrine therapy adherence in breast cancer patients diagnosed in Iceland 2013-2018
Laeknabladid · 02.07.2026 · 112 (0708) · 314-321
DOI: 10.17992/lbl.2026.0708.900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laeknabladid, online erschienen am 06.07.2026. Verfasst von Gerður Eva Halldors Helgadottir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Iceland. Hauptthemen laut MEDLINE: Breast Neoplasms, Aromatase Inhibitors, Antineoplastic Agents, Hormonal, Tamoxifen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Adjuvant endocrine therapy (tamoxifen/aromatase inhibitors) is used after surgery in hormone-receptor-positive breast cancer stage I-III. Administration for 5-10 years reduces recurrence and improves survival. Therapy adherence has not been assessed in Iceland. The main objective was to assess adherence to endocrine therapy among patients diagnosed with breast cancer in Iceland 2013-2018. Prognostic factors and the effect of adherence on prognosis were examined. Material and methods: This retrospective, population-based cohort study obtained data from the Icelandic Cancer Registry, the Icelandic Prescription Medicine Register and medical records. Treatment adherence was defined as prescription refills for tamoxifen and/or aromatase inhibitors for five years or until the day of death/recurrence of breast cancer. Patients were considered adherent if prescriptions covered ≥80% of the treatment period. Descriptive statistics, logistic regression analysis, and Kaplan-Meier survival analysis were performed.
Results
The study included 1,008 patients, 990 women and 18 men, with a median age of 62.0 years. Logistic regression identified chemotherapy before and/or after surgery as a positive predictor (OR 2.04; 95%CI 1.36-3.10; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, University of Iceland.
- Medical School, University of Iceland, Department of Internal Medicine, Landspitali University Hospital.
- University of Iceland.
- Medical School, University of Iceland, Department of Oncology, Landspitali University Hospital.
Zitieren
APA
Halldors Helgadottir, G. E., Valdimarsdottir, A. S., Finnsdottir, S. K., Lund, S. H., Haraldsdottir, S., & Bjarnadottir, O. K. (2026). Adjuvant endocrine therapy adherence in breast cancer patients diagnosed in Iceland 2013-2018. Laeknabladid, 112(0708), 314-321. https://doi.org/10.17992/lbl.2026.0708.900
Vancouver
Halldors Helgadottir GE, Valdimarsdottir AS, Finnsdottir SK, Lund SH, Haraldsdottir S, Bjarnadottir OK. Adjuvant endocrine therapy adherence in breast cancer patients diagnosed in Iceland 2013-2018. Laeknabladid. 2026;112(0708):314-321. doi:10.17992/lbl.2026.0708.900
BibTeX
@article{HalldorsHelgadottir2026,
author = {Halldors Helgadottir, Gerður Eva and Valdimarsdottir, Anita Sol and Finnsdottir, Stefania Katrin and Lund, Sigrun Helga and Haraldsdottir, Sigurdis and Bjarnadottir, Olof Kristjana},
title = {Adjuvant endocrine therapy adherence in breast cancer patients diagnosed in Iceland 2013-2018},
journal = {Laeknabladid},
year = {2026},
volume = {112},
number = {0708},
pages = {314--321},
doi = {10.17992/lbl.2026.0708.900}
}
EUVIMED